Ravulizumab Biosimilar - Research Grade

Human

Complement C5

>1mg/ml

Human IgG2(H268Q/F300Y/V309L/A330S/P331S/T339A)-G4 (M428L/N434S)-kappa

CHO Cells

Eculizumab Biosimilar - Research Grade (ICH4005), Vilobelimab Biosimilar - Research Grade (ICH5285), Pozelimab Biosimilar - Research Grade (ICH5295), Crovalimab Biosimilar - Research Grade (ICH5457), Olendalizumab Biosimilar - Research Grade (ICH5727), Omoprubart Biosimilar - Research Grade (ICH5731), Pexelizumab Biosimilar - Research Grade (ICH5771), Tesidolumab Biosimilar - Research Grade (ICH5918)

https://www.imgt.org/mAb-DB/

ICH3002

P01031

Blue ice

This product is a research-grade biosimilar of ravulizumab, supplied as an unconjugated, non-therapeutic analog built around the complement component C5 target for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic use. Ravulizumab is a long-acting, humanized monoclonal antibody engineered from eculizumab with amino acid substitutions in the Fc and complementarity-determining regions that promote pH-dependent dissociation of C5 within the acidic endosome and FcRn-mediated antibody recycling, substantially extending serum half-life. The molecule carries an engineered IgG2/IgG4 hybrid framework with the M428L/N434S half-life-extending mutations reflected in the stated isotype. As a research reagent it provides a well-characterized, sequence-defined tool for studying terminal complement inhibition, C5 binding, and pathway blockade in controlled in-vitro systems. It is offered at low endotoxin, in-vivo research-grade standards and in bulk milligram-to-gram quantities suitable for functional assays, benchmarking, and assay development. All content here is guidance for ichorbio to review before publication. Complement component C5 (UniProt P01031) is a central effector of the terminal complement pathway. Following activation of the classical, lectin, or alternative pathways, C5 convertases cleave C5 into C5a and C5b. C5a is a potent anaphylatoxin and chemoattractant that drives inflammation, neutrophil activation, and vascular permeability, while C5b nucleates assembly of the C5b-9 membrane attack complex (MAC), which forms lytic pores in target-cell membranes. Dysregulated terminal complement activity underlies conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Antibodies that bind C5 and block its cleavage prevent generation of both C5a and the MAC, sparing upstream opsonization and immune-complex clearance. Ravulizumab binds C5 with pH-sensitive kinetics, enabling target release and sustained inhibition. C5 is a human protein, making it the relevant species context for this reagent.

ALXN1210, ALXN-1210, complement 5, C5a anaphylatoxin

Detects human Complement C5

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.